Bausch Health Companies (NYSE:BHC) Sees Strong Trading Volume

Bausch Health Companies Inc. (NYSE:BHC) shares saw unusually-high trading volume on Tuesday . Approximately 146,533 shares were traded during mid-day trading, a decline of 96% from the previous session’s volume of 3,358,736 shares.The stock last traded at $28.04 and had previously closed at $26.11.

BHC has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Bausch Health Companies in a research note on Thursday, July 8th. Barclays cut their price objective on Bausch Health Companies from $35.00 to $31.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 4th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $32.64.

The firm has a market capitalization of $9.99 billion, a P/E ratio of -7.78, a P/E/G ratio of 0.55 and a beta of 1.71. The stock has a fifty day simple moving average of $28.20 and a two-hundred day simple moving average of $29.84. The company has a debt-to-equity ratio of 39.55, a current ratio of 0.99 and a quick ratio of 0.79.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Monday, August 2nd. The company reported $0.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.02. The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.12 billion. Bausch Health Companies had a positive return on equity of 1,271.62% and a negative net margin of 15.18%. As a group, sell-side analysts expect that Bausch Health Companies Inc. will post 4.24 EPS for the current fiscal year.

In other Bausch Health Companies news, Director Schutter Richard U. De bought 10,000 shares of the stock in a transaction on Wednesday, August 4th. The stock was acquired at an average cost of $25.01 per share, for a total transaction of $250,100.00. Following the completion of the acquisition, the director now owns 317,109 shares in the company, valued at approximately $7,930,896.09. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.75% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BHC. Atlas Capital Advisors LLC bought a new stake in shares of Bausch Health Companies during the first quarter valued at approximately $27,000. BDO Wealth Advisors LLC bought a new stake in shares of Bausch Health Companies during the first quarter valued at approximately $36,000. Heritage Wealth Advisors bought a new stake in shares of Bausch Health Companies during the second quarter valued at approximately $42,000. Tarbox Family Office Inc. bought a new stake in shares of Bausch Health Companies during the second quarter valued at approximately $59,000. Finally, Ameritas Investment Company LLC bought a new stake in shares of Bausch Health Companies during the first quarter valued at approximately $67,000. Hedge funds and other institutional investors own 70.31% of the company’s stock.

Bausch Health Companies Company Profile (NYSE:BHC)

Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.

Featured Article: Why do earnings reports matter?

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.